Ortho's Eprex (erythropoietin)
Executive Summary
Ortho's Eprex (erythropoietin): Preliminary results of trial for severe anemia associated with AZT therapy in AIDS patients shows "reduction in blood transfusion requirements," Ortho VP-Biotechnology and Development Seth Rudnick, MD, reported at the Oct. 12-American Association of Blood Banks meeting. Ortho licenses the recombinant human erythropoietin product from Amgen.
You may also be interested in...
France Rejects Advice To Delay Second Dose Of Pfizer Vaccine
The French government has decided not to extend the recommended interval between the two doses of the Pfizer/BioNTech coronavirus vaccine.
Biosimilars Boost Offsets Generics Slide For Sandoz
Despite the turbulence of 2020 and the pressures of the coronavirus pandemic, Sandoz has reported steady sales for the year, as biopharmaceuticals sales up by a fifth offset a slide in turnover from retail generics.
Speculation Over Moderna Vaccine Deal With Tata, Wockhardt
Moderna is speculated to be in talks with Indian firms, including Wockhardt and a Tata group company, for manufacturing its COVID-19 vaccine. A deal in India could help the company meet its obligation to supply COVAX but Moderna is likely to choose its partner carefully.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: